New hope for Hard-to-Treat lobular breast cancer?
NCT ID NCT07229417
First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times
Summary
This phase 2 trial is testing a drug called ivonescimab in people with a specific type of breast cancer called invasive lobular carcinoma that has spread and no longer responds to hormone therapy. The study includes 29 adults whose cancer is either hormone-receptor positive or triple negative. The goal is to see if ivonescimab can help control the cancer and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (a drug given by IV)
- What this could lead to
- If it works, this could point toward a new treatment option for hard-to-treat lobular breast cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is a small, early-phase trial with only 29 participants, so results may not apply widely. The drug may cause side effects or fail to control the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC ENDOCRINE REFRACTORY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.